HBcAb positivity is an independent risk factor for HIV viral blips in HIV-HBV co-infected patients on antiretroviral therapy

被引：0
|
作者：
Malagnino, V. [1 ]
Cerva, C. [1 ]
Maffongelli, G. [2 ]
Teti, E. [2 ]
Biland, L. Foroghi [1 ]
Cesta, N. [1 ]
De Masi, M. [1 ]
Andreoni, M. [1 ]
Sarmati, L. [1 ]
机构：
[1] Policlin Tor Vergata Rome, Clin Infect Dis, Rome, Italy
[2] Tor Vergata Univ, Dept Syst Med, Rome, Italy
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P250
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Management of HIV-2 resistance to antiretroviral therapy in a HIV-1/HIV-2/HBV co-infected patient
    Margarida Cardoso
    Joana Vasconcelos
    Teresa Baptista
    Isabel Diogo
    Fátima Gonçalves
    Kamal Mansinho
    Perpétua Gomes
    AIDS Research and Therapy, 18
  • [32] Management of HIV-2 resistance to antiretroviral therapy in a HIV-1/HIV-2/HBV co-infected patient
    Cardoso, Margarida
    Vasconcelos, Joana
    Baptista, Teresa
    Diogo, Isabel
    Goncalves, Fatima
    Mansinho, Kamal
    Gomes, Perpetua
    AIDS RESEARCH AND THERAPY, 2021, 18 (01)
  • [33] Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy
    Mohareb, Amir M.
    Kouame, Gerard Menan
    Gabassi, Audrey
    Gabillard, Delphine
    Moh, Raoul
    Badje, Anani
    Emieme, Arlette
    Maylin, Sarah
    Menan, Herve
    Hyle, Emily P.
    Delaugerre, Constance
    Danel, Christine
    Anglaret, Xavier
    Lacombe, Karine
    Eholie, Serge P.
    Boyd, Anders
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (04) : 621 - 629
  • [34] Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C
    Young, J.
    Mucsi, I.
    Rollet-Kurhajec, K. C.
    Klein, M. B.
    HIV MEDICINE, 2016, 17 (05) : 373 - 379
  • [35] High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China
    Jia, Hui-Hua
    Li, Kai-Wen
    Chen, Qin-Yan
    Wang, Xue-Yan
    Harrison, Tim J.
    Liang, Shu-Jia
    Yang, Qing-Li
    Wang, Chao
    Hu, Li-Ping
    Ren, Chuang-Chuang
    Fang, Zhong-Liao
    INTERVIROLOGY, 2018, 61 (03) : 123 - 132
  • [36] Management of hepatitis C in HIV and/or HBV co-infected patients
    Vicente Fernandez-Montero, Jose
    Soriano, Vicente
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2012, 26 (04) : 517 - 530
  • [37] HIV-HBV coinfection among South African patients receiving antiretroviral therapy
    Di Bisceglie, Adrian M.
    Maskew, Mhairi
    Schulze, Doreen
    Reyneke, Anne
    McNamara, Lynne
    Firnhaber, Cindy
    ANTIVIRAL THERAPY, 2010, 15 (03) : 499 - 503
  • [38] Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients
    Punyawudho, Baralee
    Thammajaruk, Narukjaporn
    Thongpeang, Parawee
    Matthews, Gail
    Lewin, Sharon R.
    Burger, David
    Ruxrungtham, Kiat
    Avihingsanon, Anchalee
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (11) : 947 - 954
  • [39] Impact of HBeAg status on immune recovery in HIV/HBV co-infected patients after highly active antiretroviral therapy
    Nie, Yuan
    Deng, XiZi
    Lan, Yun
    Li, Linghua
    Cai, Weiping
    Li, Feng
    Hu, FengYu
    INFECTION GENETICS AND EVOLUTION, 2021, 91
  • [40] Evaluation of HIV/HBV Co-Infected Cases
    Inci, Ayse
    Fincanci, Muzaffer
    Soysal, Ferda
    JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2015, 6 (04) : 439 - 442
12345